Enhancing immune response against brain tumors using specialized vesicles.
Official title: Boosting IL-12-induced anti-glioblastoma activity via immunotherapeutic extracellular vesicles.
Funded at Massachusetts General Hospital · NIH-10993191 · Data updated 2026-11-12
This study is looking at a new way to help people with glioblastoma, a tough brain cancer, by using tiny particles to make a treatment called interleukin-12 work better, which could improve their chances after their cancer comes back.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $160,561 |
| NIH project number | 5K22CA282019-02 |
| Project ID | NIH-10993191 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with recurrent glioblastoma who have limited treatment options after initial therapies.
✕Less likely to help
Patients with newly diagnosed glioblastoma who have not yet undergone treatment may not benefit from this specific research.
What this research studies
This research focuses on improving treatment options for patients with glioblastoma, a type of aggressive brain cancer. The approach involves using extracellular vesicles to boost the effects of interleukin-12, a substance that can enhance the immune system's ability to fight tumors. By combining these elements, the research aims to develop a new strategy that could lead to better outcomes for patients whose cancer has returned after initial treatment. The project also emphasizes the professional development of the lead researcher, ensuring a strong foundation for future advancements in cancer therapy.
Why it matters
Potential benefit: If successful, this research could provide a new, more effective treatment option for patients with recurrent glioblastoma, potentially extending survival and improving quality of life.
How similar studies have gone: Previous research has shown promising results with similar immunotherapeutic approaches in treating glioblastoma, indicating potential for success in this novel strategy.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Breyne, Koen — Massachusetts General Hospital
- Study coordinator: Breyne, Koen
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.